Type 1 Diabetes

Children in the U.K. with type 1 diabetes saw decreases in HbA1c and mean blood glucose levels after the country’s COVID-19 lockdown began compared with before, according to data presented at the ENDO annual meeting.

Children with type 1 diabetes have an increased risk for developing neurodevelopment disorders, with the risk greater for those with a high HbA1c, according to a study published in Diabetologia.

A higher baseline time in range is the strongest predictor of glucose response with a closed-loop insulin delivery system for children with type 1 diabetes, according to data published in Diabetes Technology & Therapeutics.

Type 2 diabetes agents with proven cardiovascular benefit may be useful for patients with type 1 diabetes to prevent atherosclerotic CVD, but more robust data are needed for the type 1 population.

The FDA granted fast track designation to VX-880, a human stem cell-derived therapy for patients with type 1 diabetes, according to the agent’s manufacturer.

A single 14-day course of the monoclonal antibody teplizumab had lasting effects on delay of type 1 diabetes diagnosis and improved beta-cell function for high-risk individuals, according to new data.

Cardiovascular and metabolic derangements observed among adolescents with type 1 diabetes and obesity parallel those of youths with type 2 diabetes, suggesting a critical need for lifestyle management, data show.

Women who had type 1 diabetes onset before menarche have a reproductive period nearly 3 years shorter than women without diabetes, according to a study published in Menopause.

A recent trial demonstrated that weekly semaglutide injections were associated with substantial weight loss in patients with obesity. It was the top story in endocrinology last week.

Adults with type 1 diabetes using a fully closed-loop, bihormonal artificial pancreas experienced improved glucose response compared with insulin pump therapy without the need to provide meal or exercise announcements, outpatient data show.